ATN-161 Inhibitor – Trifluoroacetate Salt

Name: ATN-161 Inhibitor; Trifluoroacetate Salt; MyBioSource
Brand: MyBioSource
SKU: MBS5752734
Availability: InStock
Rating: 5 (10 reviews)

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5752734

ATN-161 trifluoroacetate salt is a novel integrin alpha5beta1 antagonist that inhibits angiogenesis and growth of liver metastases in a murine model. More details

Please Inquire

Product Documentation

Sample Manual Insert View PDF

Testing Data View PDF

Certificate of Analysis (COA) View PDF

QC Report View PDF

Material Safety Data Sheet View PDF

Technical Datasheet View PDF

Protocol View PDF

Product Overview

Online Datasheet in PDF

Product Name

ATN-161 trifluoroacetate salt, Inhibitor

Full Product Name

ATN-161 trifluoroacetate salt

Product Gene Name

ATN-161, inhibitor

Product Synonym Names

ATN-161 TFA salt

Form/Format

Solid. Powder

Purity/Purification

98.00%

Preparation and Storage

Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent

Molecular Weight

711.67

Solubility

DMSO: 1mg/mL (1.41mM) Need ultrasonic
(<1mg/ml refers to the product slightly soluble or insoluble)

Formula

C25H36F3N9O10S

SMILES

OC(=O)C(F)(F)F.CC(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(N)=O

CAS Number

904763-27-5

Target & IC50

Integrin alpha5beta1

In Vitro

The combination of ATN-161 plus 5-FU significantly reduces tumor cell proliferation compared to control and single-agent therapy. In addition, combination therapy leads to a significant increase of apoptotic (TUNEL-positive) tumor cells, whereas single-agent therapy does not increase in TUNEL-positive tumor cells. ATN-161 treatment, leads to a significant reduction in EC number (21% decrease) after a 48 hr incubation time compared to control [1]. ATN-161 inhibits VEGF-induced migration and capillary tube formation in hCECs, but did not inhibit proliferation. ATN-161 decreases the number of cells migrating in response to VEGF in a dose-dependent manner starting at 100nM (P<0.001 vs. VEGF group) [2].

Product Categories/Family for ATN-161, inhibitor

Cytoskeletal Signaling

Product References and Citations for ATN-161, inhibitor

Stoeltzing O, et al. Inhibition of integrin alpha5beta1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice. Int J Cancer. 2003 Apr 20;104(4):496-503.
Stoeltzing O, et al. Inhibition of integrin alpha5beta1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice. Int J Cancer. 2003 Apr 20;104(4):496-503.
Wang W, et al. The antiangiogenic effects of integrin alpha5beta1 inhibitor (ATN-161) in vitro and in vivo. Invest Ophthalmol Vis Sci. 2011 Sep 14;52(10):7213-20.
Wang W, et al. The antiangiogenic effects of integrin alpha5beta1 inhibitor (ATN-161) in vitro and in vivo. Invest Ophthalmol Vis Sci. 2011 Sep 14;52(10):7213-20.

Other Notes

Small volumes of ATN-161, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for ATN-161 purchase

MBS5752734 is an inhibitor targeting ATN-161. Also known as ATN-161 trifluoroacetate salt.